NCT04829383 - A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG

Atezolizumab

1,200 mg

DRUG

Bevacizumab

15 mg/kg

Trial Locations (7)

New York University Clinical Cancer Center, New York

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

Univeristy of Wisconsin, Madison

University of Illinois Cancer Center, Chicago

University of Nebraska Medical Center, Omaha

DHR Health Institute for Research and Development, Edinburg

Rutgers Cancer Institute of New Jersey, New Brunswick